143 related articles for article (PubMed ID: 29432588)
1. METHOD FOR OCCUPATIONAL SKIN DOSE ESTIMATION IN UPPER EXTREMITY 131I-MIBG CONTAMINATION.
Magill D; Beckmann N; Felice M; Harkins M
Radiat Prot Dosimetry; 2018 Oct; 181(3):214-220. PubMed ID: 29432588
[TBL] [Abstract][Full Text] [Related]
2. 131I INTERNAL CONTAMINATION AND COMMITTED DOSE ASSESSMENT AMONG NUCLEAR MEDICINE MEDICAL PERSONNEL.
Brudecki K; Kluczewska-Galka A; Mróz T; Jarzab B; Zagrodzki P; Janowski P
Radiat Prot Dosimetry; 2018 May; 179(3):275-281. PubMed ID: 29237081
[TBL] [Abstract][Full Text] [Related]
3. A methodology for auto-monitoring of internal contamination by 131I in nuclear medicine workers.
Vidal MV; Dantas AL; Dantas BM
Radiat Prot Dosimetry; 2007; 125(1-4):483-7. PubMed ID: 17766259
[TBL] [Abstract][Full Text] [Related]
4. Is it safe to work with iodine-131 if you are pregnant? A risk assessment for nuclear medicine staff involved with cleaning and decontamination.
Barber RW; Parkin A; Goldstone KE
Nucl Med Commun; 2003 May; 24(5):571-4. PubMed ID: 12717076
[TBL] [Abstract][Full Text] [Related]
5. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.
Turpin BK; Morris VR; Lemen L; Weiss BD; Gelfand MJ
Health Phys; 2013 Feb; 104(2 Suppl 1):S43-6. PubMed ID: 23287519
[TBL] [Abstract][Full Text] [Related]
6. An overview on extremity dosimetry in medical applications.
Vanhavere F; Carinou E; Donadille L; Ginjaume M; Jankowski J; Rimpler A; Sans Merce M
Radiat Prot Dosimetry; 2008; 129(1-3):350-5. PubMed ID: 18448440
[TBL] [Abstract][Full Text] [Related]
7. ASSESSMENT OF INTAKE ACCORDING TO IDEAS GUIDANCE: CASE STUDY.
Bitar A; Maghrabi M
Radiat Prot Dosimetry; 2018 Apr; 179(2):179-183. PubMed ID: 29145639
[TBL] [Abstract][Full Text] [Related]
8. Extremity exposure in nuclear medicine: preliminary results of a European study.
Sans Merce M; Ruiz N; Barth I; Carnicer A; Donadille L; Ferrari P; Fulop M; Ginjaume M; Gualdrini G; Krim S; Mariotti F; Ortega X; Rimpler A; Vanhavere F; Baechler S
Radiat Prot Dosimetry; 2011 Mar; 144(1-4):515-20. PubMed ID: 21233097
[TBL] [Abstract][Full Text] [Related]
9. Skin contamination of nuclear medicine technologists: incidence, routes, dosimetry and decontamination.
Covens P; Berus D; Caveliers V; Struelens L; Verellen D
Nucl Med Commun; 2012 Oct; 33(10):1024-31. PubMed ID: 22781847
[TBL] [Abstract][Full Text] [Related]
10. [Examination of occupational exposure to medical staff (primarily nurses) during 131I medical treatments].
Watanabe M; Ishikawa N; Ito K; Ito K
Kaku Igaku; 2004 Feb; 41(1):25-31. PubMed ID: 15171456
[TBL] [Abstract][Full Text] [Related]
11. Measurement of
Brudecki K; Kowalska A; Zagrodzki P; Szczodry A; Mroz T; Janowski P; Mietelski JW
Radiat Environ Biophys; 2017 Mar; 56(1):19-26. PubMed ID: 28040836
[TBL] [Abstract][Full Text] [Related]
12. The patient as a radioactive source: an intercomparison of survey meters for measurements in nuclear medicine.
Uhrhan K; Drzezga A; Sudbrock F
Radiat Prot Dosimetry; 2014 Nov; 162(1-2):101-4. PubMed ID: 25071244
[TBL] [Abstract][Full Text] [Related]
13. Assessment of exposure of workers to ionizing radiation from radioiodine and technetium in nuclear medicine departmental facilities.
Krajewska G; Pachocki KA
Med Pr; 2013; 64(5):625-30. PubMed ID: 24502125
[TBL] [Abstract][Full Text] [Related]
14. Excretion of volatile ¹³¹I from rats following administration of Na¹³¹I or MIBG-¹³¹I.
Li C; Sadi B; Wyatt H; Bugden M; Wilkinson D; Cornett J; Kramer GH
Radiat Prot Dosimetry; 2012 Jan; 148(2):143-8. PubMed ID: 21307022
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
[TBL] [Abstract][Full Text] [Related]
16. Effective method of measuring the radioactivity of [ 131I]-capsule prior to radioiodine therapy with significant reduction of the radiation exposure to the medical staff.
Lützen U; Zhao Y; Marx M; Imme T; Assam I; Siebert FA; Culman J; Zuhayra M
J Appl Clin Med Phys; 2016 Jul; 17(4):59-72. PubMed ID: 27455475
[TBL] [Abstract][Full Text] [Related]
17. Establishing a threshold for 131I bioassay in nuclear medicine personnel.
Liang Y; Chu RY; Galbraith WK; Macdurmon GW; Sonnad JR
Health Phys; 2008 Nov; 95(5 Suppl):S175-9. PubMed ID: 18849711
[TBL] [Abstract][Full Text] [Related]
18. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
19. Behavior of Na131I and meta(131I) iodobenzylguanidine (MIBG) in municipal sewerage.
Fenner FD; Martin JE
Health Phys; 1997 Aug; 73(2):333-9. PubMed ID: 9228168
[TBL] [Abstract][Full Text] [Related]
20. Beta radiation exposure of medical staff and implications for extremity dose monitoring.
Rimpler A; Barth I
Radiat Prot Dosimetry; 2007; 125(1-4):335-9. PubMed ID: 17223637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
